The outcomes from this study might be useful for the identification and development of repurposed HDAC1 inhibitors with promising affinity towards the target protein and acceptable efficacy in the treatment of diseases associated with HDAC1, including cancer and neurodegenerative diseases. This evidence concerns the gene HDAC1 and neurodegenerative disease.